Jaguar Animal Health

Jaguar Animal Health, a tradename of Jaguar Health (NASDAQ: JAGX), supports the health and well-being of dogs, dairy calves, and foals. Our plant-based gastrointestinal products include Canalevia®-CA1, the only FDA conditionally approved drug to treat chemotherapy-induced diarrhea (CID) in dogs, and our sustainably harvested Neonorm™ Calf and Neonorm™ Foal products for managing dehydration. Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy/